Biogen Inc. announced that it has received a Complete Response Letter from the FDA for its supplemental Biologic License Application (sBLA) for a new subcutaneous route of administration… read more.
GW Pharmaceuticals plc announced that the European Commission (EC) has approved the Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with TSC,… read more.
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.
Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Enspryng (satralizumab) as the first subcutaneous treatment option… read more.
Biogen announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).
New research shows how drinking sugary beverages early in life may lead to impaired memory in adulthood. The study, published today in Translational Psychiatry, also is the first to… read more.
Researchers at Trinity College Dublin are to participate in an early phase gene-based clinical trial for motor neuron disease (MND). The research team represents one of only four… read more.
Article written by Gary Finnegan. A study of more than 250,000 women in France has found that prolonged high dose use of cyproterone acetate is associated with an… read more.
Scientists at Trinity College Dublin announced a significant advance in our understanding of an early onset form of dementia that may also progress our understanding of conditions such… read more.
A comprehensive international study, led by Monash University researchers, has definitively found that pregnancy can delay the onset of multiple sclerosis (MS) by more than 3 years. MS… read more.
Novartis announced new Mayzent (siponimod) data in the April supplemental issue of Neurology, the medical journal of the American Academy of Neurology. The data build on existing clinical… read more.
Novartis announced that clinical data for Aimovig (erenumab) was reported in Neurology . The data strengthens the role Aimovig as a preventive migraine treatment and confirms its real-world… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
